TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zelira Therapeutics ( (AU:ZLD) ) just unveiled an announcement.
Zelira Therapeutics Limited announced the issuance of 580,270 unquoted convertible notes as part of a previously announced transaction. This move is part of the company’s strategic financial management, potentially impacting its capital structure and providing additional resources for its ongoing projects and market expansion efforts.
The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based medicines. The company targets various therapeutic areas, including pain management, sleep disorders, and anxiety, aiming to leverage the potential benefits of cannabinoids to address unmet medical needs.
Average Trading Volume: 6,042
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.93M
See more data about ZLD stock on TipRanks’ Stock Analysis page.